Filing Details

Accession Number:
0001209191-19-013821
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-02-26 19:32:14
Reporting Period:
2019-02-22
Accepted Time:
2019-02-26 19:32:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
879407 Arrowhead Pharmaceuticals Inc. ARWR Pharmaceutical Preparations (2834) 460408024
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1156207 B Douglas Given 225 S. Lake Avenue
Suite 1050
Pasadena CA 91101
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-02-22 3,000 $18.05 175,130 No 4 S Direct
Common Stock Acquisiton 2019-02-26 30,000 $5.19 205,130 No 4 M Direct
Common Stock Acquisiton 2019-02-26 18,000 $2.19 223,130 No 4 M Direct
Common Stock Acquisiton 2019-02-26 10,000 $2.62 233,130 No 4 M Direct
Common Stock Acquisiton 2019-02-26 7,000 $4.75 240,130 No 4 M Direct
Common Stock Disposition 2019-02-26 65,000 $19.25 175,130 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2019-02-26 30,000 $0.00 30,000 $5.19
Common Stock Stock Option (right to buy) Disposition 2019-02-26 18,000 $0.00 18,000 $2.19
Common Stock Stock Option (right to buy) Disposition 2019-02-26 10,000 $0.00 10,000 $2.62
Common Stock Stock Option (right to buy) Disposition 2019-02-26 7,000 $0.00 7,000 $4.75
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
35,000 2013-02-16 2022-02-16 No 4 M Direct
17,000 2014-03-21 2023-03-21 No 4 M Direct
7,000 2013-09-28 2022-09-28 No 4 M Direct
0 2014-09-21 2023-09-21 No 4 M Direct
Footnotes
  1. Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
  2. The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.92 to $18.18, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
  3. The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.25 to $19.30, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
  4. Options fully vested on the 1 year anniversary of the grant date.